Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.36 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899702 | 1.00 | PTGES (0.41) | PTGESSCN10ADPP4DPP7CD38 | |
| SCHEMBL16882989 | 1.00 | PTGES (0.41) | PTGESSCN10ADPP4DPP7CD38 | |
| SCHEMBL9942006 | 0.94 | PTGES (0.42) | PTGESSCN10ADPP4DPP7CD38 | |
| SCHEMBL14233866 | 0.94 | PTGES (0.42) | PTGESSCN10ADPP4DPP7CD38 | |
| SCHEMBL9899978 | 0.88 | PTGES (0.43) | PTGESSCN10AMAP3K5MAP3K6 | |
| SCHEMBL9899974 | 0.88 | PTGES (0.43) | PTGESSCN10AMAP3K5MAP3K6 | |
| SCHEMBL14211213 | 0.87 | RAB9A (0.43) | MAP3K5MAP3K6 | |
| SCHEMBL9942022 | 0.86 | PTGES (0.41) | PTGESCD38 | |
| SCHEMBL14233420 | 0.86 | PTGES (0.41) | PTGESCD38 | |
| SCHEMBL9899780 | 0.86 | ALDH1A1 (0.40) | PTGESSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649071-B1 | Imidazo(4,5-b)pyridine-6-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2649071-A1 | IMIDAZO(4,5-B)PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8486968-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120309755-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2012076674-A1 | IMIDAZO(4,5-B)PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309755-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | PTGES 3/4885SCN10A 3537/4885DPP4 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.